| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/25/2009 | EP2026790A2 Co-therapy for the treatment of epilepsy and related disorders |
| 02/25/2009 | EP2026789A2 Novel formulation, oriented to tumour physiology, of a cytostatic, in particular of cis-platinum |
| 02/25/2009 | EP2026788A1 Therapeutic combination for painful medical conditions |
| 02/25/2009 | EP2026787A1 Tablet formulation comprising repaglinide and metformin |
| 02/25/2009 | EP2026786A2 Use of choline-based preparations for the treatment of tinnitus |
| 02/25/2009 | EP2026785A1 Propellant-free inhalation aerosol formulation containing ipratropium bromide and salbutamol sulfate |
| 02/25/2009 | EP2026784A1 Aerosol formulation containing ipratropium bromide and salbutamol sulfate |
| 02/25/2009 | EP2026783A2 Method for enhancing cognitive function |
| 02/25/2009 | EP2026782A2 N1,n4-bis(buta-1,3-dienyl)butane-1,4-diamine pharmaceutical compositions and uses thereof |
| 02/25/2009 | EP2026781A2 Pharmaceutical preparation based on myrtucommulone a for the selective tumour and cancer therapy |
| 02/25/2009 | EP2026780A1 Composition for the treatment of resistant cancers comprising oridonin |
| 02/25/2009 | EP2026779A1 Use of a composition consisting of a combination of hydroquinone, fluocinolone acetonide and tretinoin, intended for treatment signs of photoaging of the skin |
| 02/25/2009 | EP2026778A2 Use of a rar antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects |
| 02/25/2009 | EP2026775A2 Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders |
| 02/25/2009 | EP2026774A1 Improved method of treatment of bacterial infections |
| 02/25/2009 | EP2026771A2 Microspheres comprising nanocapsules containing a lipophilic drug |
| 02/25/2009 | EP2026769A1 Bilayer tablet for preventing cardiovascular events |
| 02/25/2009 | EP2026768A2 Multiple unit pharmaceutical formulation |
| 02/25/2009 | EP2026766A1 Tablet composition with a prolonged release of tamsulosin |
| 02/25/2009 | EP2026764A1 A sustained-release intraocular implant comprising a vasoactive agent |
| 02/25/2009 | EP2026763A1 A method to reduce the symptoms of heartburn and gastro-oesophageal reflux disease (gerd) by specific polysaccharides |
| 02/25/2009 | EP2026762A1 Inhalant aerosol formulations containing ethanol |
| 02/25/2009 | EP2026761A1 Inhalant propellant-free aerosol formulation |
| 02/25/2009 | EP2026659A2 Compounds for the treatment of metabolic disorders |
| 02/25/2009 | EP2026654A2 Macrophage migration inhibitory factor antagonists and methods of using same |
| 02/25/2009 | EP2026653A2 Administration of the reg1 anticoagulation system |
| 02/25/2009 | EP2026651A2 Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries |
| 02/25/2009 | EP1907370B1 Novel 1,4-benzothiazepine-1,1-dioxide derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof |
| 02/25/2009 | EP1904476B1 Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
| 02/25/2009 | EP1885695B1 Indoline compounds |
| 02/25/2009 | EP1878732B1 HIGHLY SELECTIVE Rho-KINASE INHIBITOR |
| 02/25/2009 | EP1856031B1 2-arylpropionic acid derivatives and pharmaceutical compositions containing them |
| 02/25/2009 | EP1836168B1 Benzoyl-tetrahydropyridine as glyt-1 inhibitors |
| 02/25/2009 | EP1778205B1 Hydrating composition |
| 02/25/2009 | EP1755617A4 Perfluorocarbon-soluble compounds |
| 02/25/2009 | EP1751612B1 Methods and compositions for the treatment of uveitis |
| 02/25/2009 | EP1716126B1 Morpholine derivatives as norepinephrine reuptake inhibitors |
| 02/25/2009 | EP1716113B1 Ep2- receptor agonists |
| 02/25/2009 | EP1701939B1 Anthraquinone compounds as anti cancer compounds |
| 02/25/2009 | EP1701934B1 DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY |
| 02/25/2009 | EP1680105B1 Use of glucosidase inhibitors for therapy of mucoviscidosis |
| 02/25/2009 | EP1668017B1 Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof |
| 02/25/2009 | EP1651196B1 An abuse-resistant transdermal dosage form comprising an active agent and an antagonist to said active agent |
| 02/25/2009 | EP1641801B9 Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors |
| 02/25/2009 | EP1638532B1 Flupirtin injectable galenic form |
| 02/25/2009 | EP1624848A4 Methods of hormornal treatment utilizing extended cycle contraceptive regimens |
| 02/25/2009 | EP1578726B1 Tetrahydroquinoline derivatives |
| 02/25/2009 | EP1572180B1 Use of alpha-phenylthiocarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity |
| 02/25/2009 | EP1556020B1 Use of cgrp antagonist compounds for treatment of psoriasis |
| 02/25/2009 | EP1536787A4 Imidazole alkaloids from lepidium meyenii and methods of usage |
| 02/25/2009 | EP1534675B1 Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists |
| 02/25/2009 | EP1530469B1 Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist |
| 02/25/2009 | EP1521752B1 Macrocycles for the treatment of cancer |
| 02/25/2009 | EP1506188B1 Process for the preparation of a hydrate of an anthranilic acid derivative |
| 02/25/2009 | EP1474117B1 Composition for inhalation |
| 02/25/2009 | EP1471920B1 Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 02/25/2009 | EP1392270B1 Abuse resistant pharmaceutical composition containing capsaicin |
| 02/25/2009 | EP1381361B1 Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
| 02/25/2009 | EP1365651A4 Composition and methods for modulation of vascular structure and/or function |
| 02/25/2009 | EP1254106B1 Calcilytic compounds |
| 02/25/2009 | EP1143965B1 Carbocyclic potassium channel inhibitors |
| 02/25/2009 | EP1075277B1 Methods for detecting and inhibiting angiogenesis |
| 02/25/2009 | EP1027056B1 Alpha-ketoamide multicatalytic protease inhibitors |
| 02/25/2009 | EP1015445B1 Antimicrobial quinolones, their compositions and uses |
| 02/25/2009 | EP0852587B1 Synthetic peptides that inhibit il-6 activity |
| 02/25/2009 | CN201197815Y Loratadine and pseudoephedrine sulfate sustained and controlled release capsules |
| 02/25/2009 | CN101374856A Inhibiting tumor cell invasion, metastasis and angiogenesis |
| 02/25/2009 | CN101374853A Methods and compositions for cancer therapy using a novel adenovirus |
| 02/25/2009 | CN101374849A Quinoline-4-ketones derivates as ABC transport protein regulation/control agent |
| 02/25/2009 | CN101374845A Novel compounds and use thereof |
| 02/25/2009 | CN101374844A Pyrrolopyridazinone compound |
| 02/25/2009 | CN101374843A Triazolopyridazines as tyrosine kinase modulators |
| 02/25/2009 | CN101374842A Azepinoindole derivatives as pharmaceutical agents |
| 02/25/2009 | CN101374841A Spiro imidazole derivatives as PPAR modulators |
| 02/25/2009 | CN101374840A 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors |
| 02/25/2009 | CN101374839A Azaindoles useful as inhibitors of janus kinases |
| 02/25/2009 | CN101374838A 6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile derivatives as cathepsin k and s inhibitors |
| 02/25/2009 | CN101374837A Novel heterocyclic oxime derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| 02/25/2009 | CN101374836A Muscarinic agonists and methods of use thereof |
| 02/25/2009 | CN101374835A Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors |
| 02/25/2009 | CN101374834A Compounds and methods for modulating FXR |
| 02/25/2009 | CN101374833A Novel pyrone-indole derivatives and process for their preparation |
| 02/25/2009 | CN101374832A Use of 4-imidazole derivatives for CNS disorders |
| 02/25/2009 | CN101374831A Tetrahydropyrane antibiotics |
| 02/25/2009 | CN101374830A Alpha2C adrenoreceptor agonists |
| 02/25/2009 | CN101374828A Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase |
| 02/25/2009 | CN101374825A Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators |
| 02/25/2009 | CN101374824A Heterocyclic GABA-B modulators |
| 02/25/2009 | CN101374823A Organic compounds |
| 02/25/2009 | CN101374821A 3,5-di(aryl or heteroaryl)isoxazoles and 1,2,4-oxadiazoles as S1P1 receptor agonists, immunosuppresssive and anti-inflammatory agents |
| 02/25/2009 | CN101374819A Aryl-substituted quinazolones and uses thereof |
| 02/25/2009 | CN101374817A Trisubstituted amine compound as inhibitors of cholesteryl ester transfer protein cetp |
| 02/25/2009 | CN101374815A Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (HIF) |
| 02/25/2009 | CN101374814A Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them |
| 02/25/2009 | CN101374807A Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| 02/25/2009 | CN101374803A Cyclic amine derivatives and their uses |
| 02/25/2009 | CN101374801A Histone deacetylase inhibitors for enhancing activity of antifungal agents |
| 02/25/2009 | CN101374800A Mandelic hydrazides |
| 02/25/2009 | CN101374554A Gelling hydrophobic injectable polymer compositions |
| 02/25/2009 | CN101374553A Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients |